Hormone Testing at Home
APAC · 2 shared keywords
Updated
Reviewed by Chandani Patel
APAC Cancer Genomic Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Sample, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$7.06 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.89 Bn | — | — |
| 2025 (base) | $3.28 Bn | +$392.8 Mn | — |
| 2026 (forecast) | $3.73 Bn | +$446.3 Mn | +13.6% |
| 2027 (forecast) | $4.23 Bn | +$507.0 Mn | +29% |
| 2028 (forecast) | $4.81 Bn | +$575.9 Mn | +46.6% |
| 2029 (forecast) | $5.46 Bn | +$654.2 Mn | +66.5% |
| 2030 (forecast) | $6.21 Bn | +$743.2 Mn | +89.2% |
| 2031 (forecast) | $7.05 Bn | +$844.3 Mn | +114.9% |
| 2032 (forecast) | $8.01 Bn | +$959.1 Mn | +144.1% |
| 2033 (forecast) | $9.10 Bn | +$1.09 Bn | +177.3% |
| 2034 (forecast) | $10.34 Bn | +$1.24 Bn | +215.1% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $3.28 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $10.34 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 13.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Test, sample and end user (see all) |
| Key players | Roche, Myriad Genetics, Inc., Illumina, Inc., Guardant Health, Inc., Caris Life Sciences and 1 more (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Cancer genomic tests read the DNA of tumours or blood to find mutations that guide treatment or show inherited cancer risk.
Key segments of the cancer Genomic Testing market include test (Comprehensive Genomic Profiling, Hereditary Cancer Panels and Single-Gene Tests) and sample (Tissue, Blood and Saliva).
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Genomic Testing market. Faster approvals and new combinations are improving survival.
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the cancer Genomic Testing market.
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the cancer Genomic Testing market, especially in low- and middle-income countries.
The cancer Genomic Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medical devices are regulated by TGA (Australia)[1], NMPA (China)[2], MDACS (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], MDA (Malaysia)[6], Medsafe (WAND) (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20].
[1] Therapeutic Goods Administration. Checked 14 Nov 2026.
[2] National Medical Products Administration. Checked 14 Nov 2026.
[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.
[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[6] Medical Device Authority. Checked 14 Nov 2026.
[7] Medsafe. Checked 14 Nov 2026.
[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.
[9] Health Sciences Authority. Checked 14 Nov 2026.
[10] Thai Food and Drug Administration. Checked 14 Nov 2026.
[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
[12] National Healthcare Security Administration. Checked 14 Nov 2026.
[13] Hospital Authority. Checked 14 Nov 2026.
[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.
[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
[16] Ministry of Health Malaysia. Checked 14 Nov 2026.
[17] Pharmac. Checked 14 Nov 2026.
[18] PhilHealth. Checked 14 Nov 2026.
[19] CPF Board, MediShield Life. Checked 14 Nov 2026.
[20] National Health Security Office. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how cancer Genomic Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.
What doctors and scientists are doing in Cancer Genomic Testing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
APAC · 2 shared keywords
APAC · 1 shared keyword
APAC · 1 shared keyword
APAC
APAC
APAC
Pharmaceuticals · APAC
Digital Health · APAC
Healthcare Services · APAC
Pharmaceuticals · APAC
Pharmaceuticals · APAC
Healthcare Services · APAC